HWAM
INDV icon

Hennion & Walsh Asset Management’s Indivior Pharmaceuticals INDV Stock Holding History

Hennion & Walsh Asset Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8M Buy
360,245
+29,554
+9% +$1.07M 0.42% 40
2026
Q1 		$10.1M Buy
330,691
+13,091
+4% +$432K 0.34% 52
2025
Q4 		$11.4M Buy
317,600
+96,177
+43% +$2.94M 0.39% 42
2025
Q3 		$5.34M Buy
221,423
+24,396
+12% +$511K 0.19% 127
2025
Q2 		$2.9M Buy
197,027
+54,583
+38% +$636K 0.12% 231
2025
Q1 		$1.36M Buy
142,444
+46,509
+48% +$489K 0.06% 390
2024
Q4 		$1.19M Buy
+95,935
New +$987K 0.05% 424

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hennion & Walsh Asset Management's INDV Position: Q2 2026 in Review

Hennion & Walsh Asset Management increased its Indivior Pharmaceuticals (INDV) stake by 8.9% in Q2 2026, buying an estimated $1.07M and bringing the position to 360,245 shares worth $14.8M. The position accounts for 0.42% of the portfolio, ranked #40.

Hennion & Walsh Asset Management first reported a position in INDV in Q4 2024 and has held it in 7 quarters since. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Hennion & Walsh Asset Management held 360,245 shares of Indivior Pharmaceuticals worth $14.8M as of Q2 2026.
  • Hennion & Walsh Asset Management bought 29,554 Indivior Pharmaceuticals shares in Q2 2026, an estimated $1.07M.
  • Indivior Pharmaceuticals made up 0.42% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #40 holding.
  • Hennion & Walsh Asset Management first reported a position in Indivior Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.